Gaucher disease is an autosomal recessive inherited metabolic disorder in which glucocerebroside, a form of fat/ lipid, is impotent to breakdown. Glucocerebrosidase is a body synthesis enzyme that breaks down and besides reprocesses the glucocerebroside. The Gaucher disease is triggered due to a mutation in the GBA gene, which results in very short levels of the glucocerebrosidase enzyme, resulting in poor glucocerebroside breakdown. Gaucher disease is divided into three types: type 1, type 2, and type 3. The type 1 is common, whereas type 2 and type 3 are less common.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1225
The approval of new drugs is expected to propel the global Gaucher disease treatment market growth
In recent years, the US Food and Drug Administration (FDA) had permitted a number of drugs for the Gaucher disease treatment. Vpriv (velaglucerase alfa) was approved by the U.S. FDA in 2010 as an enzyme replacement therapy (ERT) in type 1 of Gaucher disease. Elelyso (taliglucerase alfa), as well as Cerdelga (eliglustat) were permitted by the US FDA in 2012 and 2014, respectively, for treating type 1 of Gaucher disease. These medications provide a number of selections as per their needs, which is expected to drive the global Gaucher disease treatment market growth over the forecast period.
The U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA), in July 2017, partnered to encourage the adoption of novel methods in the progress of Gaucher disease medicines. The Gaucher disease treatment market growth is expected to increase as a result of such partnerships amongst regulatory authorities for the development of new innovative drugs. Lack of knowledge of disease treatment, symptoms, and diagnosis among the rural population is a key factor hindering the global Gaucher disease market growth.
Gaucher Disease Treatment Market Taxonomy
The Gaucher disease treatment market is segmented on the basis of disease type, treatment type, and distribution channel.
On the basis of disease type, the Gaucher disease treatment market is segmented into:
- Type 1 Gaucher disease
- Type 2 Gaucher disease
- Type 3 Gaucher disease
On the basis of therapy type, the Gaucher disease treatment market is segmented into:
- Enzyme Replacement Therapy (ERT)
- Substrate Reduction Therapy (SRT)
On the basis of distribution channel, the Gaucher disease treatment market is segmented into:
- Hospitals
- Retail Pharmacies
- Online Pharmacies
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1225
North America is expected to account for largest share in the global Gaucher disease treatment market due to growing research and development of drugs for Gaucher diseases treatment.
North America is expected to account for the largest share in the global Gaucher disease treatment market because of increased research initiatives for the progress of new drugs for Gaucher diseases treatment. Researchers from the National Institutes of Health cooperated with the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Neurological Disorders and Stroke (NINDS) in 2016. Researchers have discovered a novel molecule that could be used to treat the Gaucher disease. Various initiatives organized by European organizations for the awareness of Gaucher disease amongst the European community is anticipated to be the second largest Gaucher disease treatment market in Europe.
Major players operational in the global Gaucher disease treatment market are Shire Human Genetics Therapies, Actelion Pharmaceuticals Limited (in June 2017 acquired by the Johnson & Johnson), Pfizer Inc., and Genzyme Corp. There are several drugs for Gaucher disease treatment in portfolio of firms such as Pharming Group NV, Orphazyme ApS, Lixte Biotechnology Holdings, and JCR Pharmaceuticals Limited.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/1225
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837